Please login to the form below

Not currently logged in
Email:
Password:

fitusiran

This page shows the latest fitusiran news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Novo Nordisk hits pause on rival to Hemlibra for haemophilia

Meanwhile, another non-clotting factor drug for haemophilia  – Alnylam and Sanofi’s RNA interference candidate fitusiran – is also in late-stage development for haemophilia A and B.

Latest news

  • Sanofi narrows focus, shedding diabetes and cardiovascular research Sanofi narrows focus, shedding diabetes and cardiovascular research

    This includes a host of investigational therapies for rare disease and cancers, such as Fitusiran (an RNAi therapeutic for haemophilia A and B), BIVV001 (a factor VIII therapy for haemophilia A)

  • Roche’s Hemlibra scores broader NHS funding Roche’s Hemlibra scores broader NHS funding

    Competition is heating up in haemophilia, however. Alnylam's late-stage candidate fitusiran is tipped as a major competitor to Hemlibra, while the first gene therapies are also on the horizon.

  • ACPs to lead gene therapies in haemophilia market growth ACPs to lead gene therapies in haemophilia market growth

    New therapies to hit existing players. Roche’s Hemlibra and Alnylam’s late-stage candidate fitusiran are likely to seize a bigger share of an expanded haemophilia market than gene therapies, ... The two drugs have distinct mechanisms –  Hemlibra

  • Sanofi exits R&D pact with Alnylam on rare disease Sanofi exits R&D pact with Alnylam on rare disease

    The R&D deal was tweaked in January last year, with Sanofi licensing an RNAi drug called fitusiran for haemophilia A and B as well as other rare bleeding disorders, but ... Prospects for haemophilia candidate fitusiran looked a little shaky in 2017 when

  • FDA lifts clinical hold on Sanofi’s haemophilia drug FDA lifts clinical hold on Sanofi’s haemophilia drug

    Fitusiran holds the potential to help improve the lives of people living with haemophilia,” said Akin Akinc, who is leading the development of the drug at Alnylam. ... With the additional risk mitigation measures in place, we look forward to the

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Patient recruitment and retention 2021 state of play
At COUCH Health, we’ve recently done some social listening to look into the discussions around ‘patient recruitment’ and ‘patient retention’, to see if these conversations have been impacted by the...
The UK has approved the first vaccine for COVID-19. What now?
The authorisation of Pfizer/BioNtech's mRNA vaccine by the MHRA is great news, but no-one has ever tried to roll out a vaccine as rapidly as this one, so we have...
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue....

Infographics